Bayer AG’s Innovative Phase I Study: A New Frontier in Cancer Treatment

Bayer AG ((BAYRY)), Bayer Ag (UK) ((GB:0P6S)) announced an update on their ongoing clinical study.

Study Overview: Bayer AG is conducting a Phase I clinical study titled Phase 1 Study of a SOS1 Inhibitor, BAY 3498264, in Combination in Participants With Advanced KRASG12C-mutated Solid Tumors. The study aims to evaluate the safety and maximum tolerable dose of BAY3498264 when combined with Sotorasib in treating advanced solid cancers with the KRASG12C mutation. This research is significant as it explores a potential enhancement of Sotorasib’s efficacy, which could lead to improved treatment outcomes for patients.

Intervention/Treatment: The study tests BAY3498264, a SOS1 inhibitor, in combination with Sotorasib, an approved drug targeting KRASG12C mutations. BAY3498264 is designed to block SOS1 protein activity, potentially extending the effectiveness of Sotorasib against cancer cells.

Study Design: This interventional study is non-randomized with a sequential intervention model. It focuses on treatment as its primary purpose and does not involve masking. Participants will initially receive BAY3498264 alone, followed by a combination with Sotorasib in 21-day cycles.

Study Timeline: The study began on November 8, 2024, with its primary completion and estimated completion dates yet to be announced. The last update was submitted on August 21, 2025. These dates are crucial for tracking the study’s progress and potential market impact.

Market Implications: The ongoing study could influence Bayer AG’s stock performance by potentially enhancing its oncology portfolio with a novel treatment approach. Positive outcomes might boost investor confidence and position Bayer competitively within the oncology sector, particularly against rivals targeting similar genetic mutations.

The study is currently recruiting, with further details available on the ClinicalTrials portal.